Why the study?
Does R68070 inhibit platelet activation and prolong bleeding time compared to aspirin and placebo in human volunteers?
Population
9 volunteers (in vivo study) and in vitro human platelets
Comparison
R68070 400 mg vs Aspirin 400 mg and placebo 400 mg
Design
RCT, randomized, cross-over, double-blind
Authors
Loading...
R68070 may offer greater antiplatelet potency than aspirin; extends rationale for dual thromboxane inhibition in antithrombotic development.
Does R68070 inhibit platelet activation and prolong bleeding time compared to aspirin and placebo in human volunteers?
R68070, a combined thromboxane synthase inhibitor and receptor antagonist, produces stronger inhibition of hemostasis than aspirin by reorienting cyclic endoperoxide metabolism toward prostacyclin.
Hoet et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: